Amylin Pharmaceuticals and Takeda Pharmaceutical Company have entered a worldwide agreement to co-develop and commercialise pharmaceutical products for the treatment of obesity and related symptoms.

The agreement includes the development of Amylin products in the second phase of development for the treatment of obesity, such as pramlintide/metreleptin and davalintide. It also includes additional compounds from each company’s obesity research programmes.

The Californian biopharmaceutical company Amylin will receive a one-off payment of $75m from the Japanese research company Takeda, and will receive additional payments depending on certain development, commercialisation and sales-based targets that could reach as much as $1bn.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData